Key result
Low-dose aspirin linked to ~40% lower all-cause mortality without increasing major bleeding.
Why the study?
The study was conducted to evaluate the benefit and risk of low-dose aspirin in patients from remote Aboriginal communities in the Northern Territory, Australia.
Does low-dose aspirin reduce all-cause and cardiovascular mortality in high-risk Aboriginal adults?
Cohort (n=8,167)
Yes
Does low-dose aspirin reduce all-cause and cardiovascular mortality in high-risk Aboriginal adults?
Aspirin for primary prevention in high-risk Aboriginal populations is associated with a significant reduction in all-cause mortality without a detectable increase in major bleeding.
Answers are grounded in this paper and cite their sources.
May support aspirin in high-risk Aboriginal adults; hypothesis-generating and should not change practice without RCTs.
OBJECTIVES: To evaluate the benefit and risk of low-dose acetylsalicylic acid (aspirin) in patients from remote Aboriginal communities in the Northern Territory, Australia. DESIGN: Retrospective cohort study using primary care and hospital data routinely used for healthcare. Aspirin users and non-users were compared before and after controlling confounders by matching. Marginal structural models (MSM) were applied to ascertain the benefit and risk. SETTING: The benefit and harm of aspirin were investigated in patients aged ≥18 years from 54 remote Aboriginal communities. PARTICIPANTS: None had a previous cardiovascular event or major bleeds. Patients on anticoagulants or other antiplatelets were excluded. INTERVENTION: Aspirin at a dose of 75-162 mg/day. OUTCOME MEASURES: Endpoints were all-cause, cardiovascular mortality and incidences of cardiovascular events and major bleeds. RESULTS: 8167 predominantly Aboriginal adults were included and followed between July 2009 and June 2017 (aspirin users n=1865, non-users n=6302, mean follow-up 4 years with hospitalisations 6.4 per person). Univariate analysis found material differences in demographics, prevalence of chronic diseases and outcome measures between aspirin users and non-users before matching. After matching, aspirin was significantly associated with reduced all-cause mortality (HR=0.45: 95% CI 0.34 to 0.60; p<0.001), but not bleeding (HR=1.13: 95% CI 0.39 to 3.26; p=0.820). After using MSMs to eliminate the effects of confounders, loss of follow-up and time dependency of treatment, aspirin was associated with reduced all-cause mortality (HR=0.60: 95% CI 0.47 to 0.76; p<0.001), independent of age (HR=1.06; p<0.001), presence of diabetes (HR=1.42; p<0.001), hypertension (HR=1.61; p<0.001) and alcohol abuse (HR=1.81; p<0.001). No association between aspirin and major bleeding was found (HR=1.14: 95% CI 0.48 to 2.73; p=0.765). Sensitivity analysis suggested these findings were unlikely to have been the result of unmeasured confounding. CONCLUSION: Aspirin was associated with reduced all-cause mortality. Bleeding risk was less compared with survival benefits. Aspirin should be considered for primary prevention in Aboriginal people with high cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2020) conducted a cohort in High cardiovascular risk (n=8,167). Aspirin vs. Non-aspirin users was evaluated on All-cause mortality (HR 0.60, 95% CI 0.47-0.76, p=<0.001). Low-dose aspirin use was associated with a 40% reduction in all-cause mortality (HR 0.60) compared to non-use in high cardiovascular risk patients, without increasing major bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: